Clinical Trial Update: Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating KN026 in combination with HB1801 as first-line therapy for HER2-positive recurrent or metastatic breast cancer, curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HB1801
• KN026

Snippet

Sponsor: Shanghai JMT-Bio Inc. | Conditions: First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer | Phase 3 | Status: RECRUITING